Victoria Ivanov

Victoria Ivanov

Auto-generated profile, based on publicly available information

Victoria Ivanov

IMSP Institutul de Cardiologie

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Verified
Journal Article
Open access
PDF file
MPMihail Popovici
Mihail Popovici
VIVictoria Ivanov
Victoria Ivanov
IPIon Popovici
Ion Popovici
LCLucia Ciobanu
Lucia Ciobanu
MMMihaela Munteanu
Mihaela Munteanu
VCValeriu Cobets
Valeriu Cobets
Aim. Assessment within the multi-marker panel applied to patients with NSTEMI of admission levels of the main markers of cardiovascular pathology in order to disentangle the pathogenetic interface and identify diagnostic predictors. Material and methods. The research was carried out on a group of 87 patients with NSTEMI, exposed to angioplas-ty, in which the admission values of 2 morphofunctional markers of endothelial dysfunction were determined, as well as the serum levels of 53 biochemical markers with reference to: inflammation, oxidative stress, endothelial dysfunction, cell injury, hemostasis disorder, myocardial and extracellular matrix (ECM) remodeling. The control group has consisted of 40 apparently healthy people.Results. The analysis of the multi-makrer panel revealed significant deviations of the majority of the explored markers compared to the control level. Endothelial dysfunction was marked by the increase of thickness of the medial-intima complex of the carotid artery and the decrease of the flow-mediated dilation of brachial artery in association with a 7694% raise of endothelial cell fragments (EF), phospholipase A2 (PhA2) and angiopoietin 2 (Ang 2). Among 16 markers of inflammation, the elevation of myeloperoxidase (MPO) by 156% is remarkable as a specific marker of NETosis. Activated oxidative stress is the result of the impairment of the antioxidant defense, and hemostasis disorder must be underlined by double increase of fibrin monomers (FM). From a pathogenetic point of view, the multiple increase (more than 8 times) of cardiac myosin-binding protein (cMyBP-C) is important and understandable, and the markers of myocardial and ECM remodeling basically demonstrated an activation of several types of metalloproteinases. Conclusion. From the spectrum of the multi-marker panel applied to patients with NSTEMI, markers with plausible diagnostic value due to inteligibly reflected pathogenetic mechanism are highlighted as: MPO, PhA2, Ang 2, EF, FM, and cMyBP-C.

1 May 2022 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
APAngela Peltec
Angela Peltec
VIVictoria Ivanov
Victoria Ivanov
ITInes Toaca
Ines Toaca
SMSergiu Matcovschii
Sergiu Matcovschii
Background. Fatty liver disease (FLD) is composed of a wide spectrum including metabolic associated fatty liver disease (MAFLD). Cardiovascular disease (CVD) is the leading cause of mortality in this populational group. Many risk estimation systems are in existence for improving the management of population groups, but currently, none of the available risk prediction models are authenticated in patients with hepatic steatosis. Materials and methods. Transversal, observational, prospective, case control study has been included 680 patients with MAFLD and 96 control subjects without MAFLD. Experimental group was divided in tree subgroups: A - overweight or obesity (BMI ≥ 25 kg/m2 ) N= 498; B – lean/normal weight (BMI <25kg/m2 ) N= 58 and C – Type 2 diabetes mellitus N= 156. For each patient, cardiovascular risk was estimated using the Framingham equation (risk ≥ 20% – high), SCORE risk chat (risk ≥ 10% – high) and Atherosclerotic Cardiovascular Disease Risk Algorithm from the American College of Cardiology and the American Heart Association (AHA/ACC) (risk ≥ 20% – high). Results. Model Risk SCORE and Risk ACC/AHA had identified the low proportion of patients with high risk, however, Risk FRS determined the highest proportion of the patients as being ‘at high-risk’ (Risk SCORE -7% vs Risk ACC/AHA - 15% vs Risk FRS - 38%, p <0.001). Statistically significant correlations were found between the scoring systems Risk FRS and Risk ACC/AHA (Pearson’s r = 0.939, p = 0.0001, Spearman`s rho=0.960, p <0.001). The highest proportion of the patients as being ‘at high-risk’ from group C – DMT2 was found by model RiskFRS – 82.7%, with statistically significant difference between group A and B – 28.1 % vs 6.8%, p < 0.001. The same tendency was observed for RiskSCORE and Risk ACC/AHA (RiskSCORE DMT2 – 26.3% vs Risk ACC/AHA DMT2 – 46.8%), bur these scores have identified the low proportion of patients with high risk in this populational group. Conclusions. The study shows that RiskFRS appeared to be most useful CVD risk assessment model in hepatic steatosis, RiskFRS is likely to identify a greater number of patients at ‘high-risk’ as compared to Risk SCORE and Risk ACC/AHA.

1 June 2023 in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Verified
Journal Article
Open access
PDF file
MPMihail Popovici
Mihail Popovici
VIVictoria Ivanov
Victoria Ivanov
IPIon Popovici
Ion Popovici
LCLucia Ciobanu
Lucia Ciobanu
MMMihaela Munteanu
Mihaela Munteanu
VCValeriu Cobet
Valeriu Cobet
Scop. Evaluarea rolului morții neutrofilelor (NET-ozei) în evoluția infarctului miocardic acut fără elevarea segmentului ST (NSTEMI) prin aprecierea nivelurilor circulante de admitere în staționar ale markerilor care au în plan fiziopatologic tangență la acest fenomen. Material și metode. Cercetarea s-a realizat pe un lot de 54 de pacienți cu NSTEMI, supuși angioplastiei coronariene în laboratorul de cardiologie intervențională în cadrul proiectului științific din cadrul Programului de stat, la care prin metoda ELISA s-a determinat conținutul seric al 7 markeri biochimici: Selectina E, moleculei de adeziune intercelulare 1(ICAM-1), fosfolipaza 2(PhA2), interleukina 8 (IL-8), elastaza neutrofilelor ( EN), mieloperoxidaza (MPO) și metaloproteinaza 8 (MMP-8). Lotul de control a fost format din 30 de persoane aparent sănătoase. Rezultate. Rezultatele obținute indică prezența devierilor incrementale semnificative ale tuturor markerilor explorați la pacienții cu NSTEMI în comparație cu nivelul control. Markerii mai specifici ai NETozei (MPO, EN și MMP-8) au excelat prin rata maximă de elevare în ser, decelată în limitele 88-151%. Ceilalți markeri au avut o rată de creștere a nivelurilor lor circulante de 50-74%. Concluzie. La pacienții cu NSTEMI nivelurile circulante de admitere ale markerilor specifici ai NET-ozei, mieloperoxidaza, elastaza neutrofilelor și MMP-8 sunt elevate cu 88-151% față de control, fapt ce indică asupra rolului patogenetic al NET-ozei și, totodată, invocă plauzibil acestor markeri valoare predictivă diagnostică și prognostică.

1 October 2025
Verified
Journal Article
Open access
PDF file
MMMihaela Munteanu
Mihaela Munteanu
EAElena Anton
Elena Anton
LCLucia Ciobanu
Lucia Ciobanu
IPIon Popovici
Ion Popovici
VIVictoria Ivanov
Victoria Ivanov
MPMihail Popovici
Mihail Popovici
Angina and ischaemia with non-obstructive coronary arteries (ANOCA/INOCA) are manifestations of chronic nonobstructive coronary artery disease (CAD) and refer to anginal symptoms or evidence of myocardial ischaemia without flow‐limiting obstructive lesions in the epicardial coronary arteries. Both entities share common vascular dysfunction mechanisms, called endotypes: endothelial dysfunction, impaired vasodilation, epicardial vasospasm, microvascular vasospasm and their combinations, and carry clinical aggravated significance by refractory angina, increased risk of major adverse cardiovascular events (MACE) and important impairment of quality of life (QoL). The updated (2024) European Society of Cardiology (ESC) guidelines for the management of chronic coronary syndromes (CCS) pay increase attention to the subject of ANOCA/INOCA, providing diagnostic and therapeutic management recommendations. In order to achieve a personalized approach based on endotype and reliable evidence, the imperative for additional clinical research emerged, which would provide new effective diagnostic strategies and treatments for patients with ANOCA/INOCA syndrome.

1 October 2025
Verified
Journal Article
Open access
PDF file
VTVictoria Tofan
Victoria Tofan
MPMihail Popovici
Mihail Popovici
SCSvetlana Cojocari
Svetlana Cojocari
VIVictoria Ivanov
Victoria Ivanov
MMMihaela Munteanu
Mihaela Munteanu
DTDiana Turlacova
Diana Turlacova
A large proportion of patients undergoing coronary angiography for angina pectoris do not have obstructive epicardial coronary arteries (ANOCA). In these patients, the prevalence of demonstrable ischemia (INOCA) varies between 10% and 30%, depending on the stress test performed. In recent years, research has focused on defining, classifying, and treating these patients according to INOCA endotypes. Inflammation and endothelial dysfunction play a key role in the onset and progression of chronic non-obstructive coronary artery disease (non-obstructive CAD), and identifying the correlation between these mechanisms and the disease itself may offer a targeted therapeutic strategy. This synthesis presents data from the last 10 years of the specialized literature, searched on Google Scholar and PubMed using keywords such as: inflammation in non-obstructive CAD, anti-inflammatory therapy in non-obstructive CAD. The selected studies, with scientific relevance, focused on the clinical importance, mechanism, evaluation, and management of non-obstructive CAD, with particular emphasis on the role of inflammation, endothelial dysfunction, and anti-inflammatory therapy

1 August 2022 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
MPMihail Popovici
Mihail Popovici
LCLucia Ciobanu
Lucia Ciobanu
VIVictoria Ivanov
Victoria Ivanov
MIMihaela Ivanov
Mihaela Ivanov
IPIon Ion Popovici
Ion Ion Popovici
VCValeriu Cobet
Valeriu Cobet
Background: Coronary thrombosis is the key pathogenic mechanism of acute heart attack, including non-ST segment elevation (NSTEMI). Given that, the detection of reliable markers of hemostasis disorders is important in the process of optimizing the diagnosis of NSTEMI. Material and methods: The study was conducted on 54 patients with NSTEMI (average age 69.7±1.5 years). In 60% of cases, 3-vessel disease was noted; 56% of patients had ejection fraction >50%, and Killip class I of heart failure was revealed in 78% of patients. With the help of the STA-Liatest (France) equipment, the blood tests determined the following hemostasis markers: fibrin monomers (FM), thrombotic complex activity of factors II, VII and X. Additional markers like Procoag, the coagulation indicator dependent on circulating phospholipids or SPA, D-dimers, as well as factors C, S and antithrombin III were appreciated. The values of these markers determined by the same method in 20 healthy persons (control group) were used as normal values. Results: Circulating level of FM on admission was increased twice, while the values of Procoag and SPA were significantly decreased by 35.3% compared to the control. Factors C, S and antithrombin III were 54-80% of the control value range, and D-dimers were within the permissible values. In the acute phase of the heart attack, a deterioration of hemostasis indicators was noted, excepting the D-dimers. The levels of FM determined 24 and 72 hours after revascularization were consistently increased (up to 3.8 times) compared to the control, while Procoag and SPA decreased by 54-57%. Further reduction of factors C, S and antithrombin III accounted for 42-54% of normal indicators. After 5 days, an improvement in hemostasis markers was observed, but a significant difference still remained comparing to the control group. Conclusions: The hemostasis particularities discovered in patients with NSTEMI indicate the features of an activated prothrombotic status, and FM could be an important diagnostic marker of NSTEMI, due to its most significant deviation from the normal value (>100%). It can reliably reflect the thrombin level, which triggers the last enzymatic phase of thrombus formation.